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ABSTRACT
Rationale Reduced physical activity (PA) in patients
with COPD is associated with a poor prognosis. Increasing
PA is a key therapeutic target, but thus far few strategies
have been found effective in this patient group.
Objectives To investigate the effectiveness of a 12-
week semiautomated telecoaching intervention on PA in
patients with COPD in a multicentre European randomised
controlled trial.
Methods 343 patients from six centres, encompassing a
wide spectrum of disease severity, were randomly allocated
to either a usual care group (UCG) or a telecoaching
intervention group (IG) between June and December 2014.
This 12-week intervention included an exercise booklet and
a step counter providing feedback both directly and via a
dedicated smartphone application. The latter provided an
individualised daily activity goal (steps) revised weekly and
text messages as well as allowing occasional telephone
contacts with investigators. PA was measured using
accelerometry during 1 week preceding randomisation and
during week 12. Secondary outcomes included exercise
capacity and health status. Analyses were based on
modified intention to treat.
Main results Both groups were comparable at baseline in
terms of factors influencing PA. At 12 weeks, the intervention
yielded a between-group difference of mean, 95% CI (lower
limit – upper limit; ll-ul) +1469, 95% CI (971 to 1965) steps/
day and +10.4, 95% CI (6.1 to 14.7) min/day moderate PA;
favouring the IG (all p≤0.001). The change in 6-min walk
distance was significantly different (13.4, 95% CI (3.40 to
23.5) m, p<0.01), favouring the IG. In IG patients, an
improvement could be observed in the functional state
domain of the clinical COPD questionnaire (p=0.03)
compared with UCG. Other health status outcomes did not
differ.
Conclusions The amount and intensity of PA can be
significantly increased in patients with COPD using a 12-week
semiautomated telecoaching intervention including a step
counter and an application installed on a smartphone.
Trial registration number: NCT02158065.
INTRODUCTION
Based on overwhelming evidence, regular physical
activity (PA) is at present seen as one of the most
powerful health-promoting acts.1 Physical inactivity
is the fourth leading cause of death, attributing to
>5 million premature deaths worldwide.2 Also,
6–10% of major non-communicable disease burden
is caused by inactivity.2 Despite this evidence, a
large proportion of healthy elderly people do not
meet PA recommendations.2 Patients with chronic
disease show an even more pronounced inactive
lifestyle.3 This is particularly true when exercise
induces symptoms.
COPD is a leading cause of mortality and morbid-
ity, resulting in a substantial economic and social
burden.4 Patients with COPD are less active than
age-matched controls.5 In this patient population,
low levels of PA are an independent risk factor for
mortality and hospitalisation.6 7 Generally, activity
level decreases with increasing disease severity but
inactivity is not simply a reflection of lung function
impairment.8 9 Activity promotion is included as a
key element in the recommendations for the man-
agement of patients with COPD, 4 although there
Key messages
What is the key question?
▸ What is the effectiveness of a 12-week
semiautomated telecoaching intervention on
objectively measured physical activity in
patients with COPD included in a multicentre
European randomised controlled trial?
What is the bottom line?
▸ A 12-week semiautomated telecoaching
intervention including a step counter and an
application installed on a smartphone is
effective in increasing the amount and intensity
of physical activity in patients with COPD.
Why read on?
▸ This article reports on an effective, innovative
and promising coaching programme for people
with COPD with a low burden on health
professionals administering it.
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are, thus far, few interventions of proven efficacy. In particular,
both pulmonary rehabilitation programmes10 and pharmacother-
apy,11 12 while of proven benefit in other respects, have led to
small and inconsistent increases in PA.
PA is a complex health behaviour; consequently, effective
behaviour change interventions need to reflect this. In chronic-
ally ill patients, larger improvements on PA have been observed
in intervention studies where behaviour strategies (goal setting,
contracting, feedback, consequences and/or cues) were
included.13 Activity monitors can provide direct feedback,
which has shown promise in COPD, in combination with goal
setting.14 15 Implementing behaviour strategies can be done by
face-to-face contacts between patients and clinicians. However,
such interventions are relatively time-consuming and may
depend on the skills and training of the clinicians involved,
making it more difficult for them to be widely adopted.
Electronic information and communication technologies offer
the possibility of decreasing the burden on clinicians and
patients, standardising interventions and making them available
to people who live in remote areas or in areas where access to
healthcare providers is limited (‘telecoaching’).16
One study in the USA has shown the effectiveness of a solely
internet-based telecoaching programme on PA in patients with
COPD, observing improvements in both health-related quality
of life and in PA.17 Various health-related applications
(‘m-health’), focusing on PA, are available on the market,18 but
applications tailored for patients with COPD have not yet been
developed nor tested. We hypothesised that a smartphone appli-
cation, specifically designed for the intended population and
allowing human contact if needed, across the whole spectrum of
COPD, would offer insight into the potential effectiveness of
such an intervention on the PA level.
We therefore assessed the effectiveness of a 12-week PA pro-
motion telecoaching programme in addition to usual care in a
multicentre trial including patients with COPD. This study
forms part of the European IMI-JU PROactive project.
METHODS
Study population
Patients with a physician-based diagnosis of COPD,4 age >40
with a smoking history of at least 10 pack-years, who were not
actively participating in a pulmonary rehabilitation programme
at the moment of inclusion (or did not plan to start),
were enrolled at six centres across Europe (Leuven (Belgium),
Athens (Greece), London and Edinburgh (the UK), Zurich
(Switzerland) and Groningen (The Netherlands)); these centres
were chosen in order to recruit patients with a range of severity
of COPD. Patients were excluded if they had any comorbidity
limiting a normal activity pattern, had another respiratory
disease as primary diagnosis or were unable to understand or
operate a smartphone device. Stable patients as well as patients
having an acute exacerbation in the last month were included in
this trial. Patients using walking aids or those on long-term
oxygen treatment were as well included in the trial.
Design
The trial consisted of three visits—a screening visit (V1), a ran-
domisation visit (V2) 1–2 weeks later and a final visit (V3),
12 weeks post randomisation. In this 1:1 randomised controlled
trial, patients were allocated in either a control group (UCG)
receiving usual care or in an intervention group (IG).
The random sequence was generated with varying block sizes of
4, 6 or 8 and stratified by centre using a statistical software
(STATA V.12.0, StataCorp, College Station, Texas, USA). After
obtaining informed consent and when all inclusion criteria were
met at V2, investigators obtained group allocation using an
online system that ensured concealment of random allocation.
Usual care
Patients in both groups received a standard leaflet explaining the
importance of PA in COPD as well as information about PA
recommendations. This leaflet was discussed with all patients in a
5–10 min one-to-one discussion with the investigator during V2.
The usual medical treatment was not altered throughout the study.
Intervention
Patients in the IG received the usual care plus the telecoaching
intervention. This intervention included several components: (1)
a one-to-one interview with the investigator during V2 discuss-
ing motivation, barriers, favourite activities and strategies to
become more active; (2) a step counter (Fitbug Air) providing
direct feedback on the step count, on a 2 × 3 cm display; (3)
smartphone with Fitbug application and a project-tailored
coaching application. This application was specifically designed
for use by patients with COPD in the present project. It pro-
vided automated coaching by displaying an activity goal
(number of steps) and feedback on a daily basis. The feedback
included a graphical representation of that day’s performance
and an educational tip. Patients’ targets were automatically
revised every Sunday, based on performance in the preceding
week (figure 1). Investigators could alter or ‘lock’ the goals if
needed, based on interaction with the patient; (4) a booklet con-
taining home exercises; (5) weekly group text message with
activity proposals sent by the investigator, taking into account
the local weather forecast; and (6) telephone contacts triggered
in the case of non-compliance with wearing the step counter,
failure to transmit data or failure to progress. More information
is provided in the online supplementary material.
Assessments
Physical activity
PA was objectively measured with the Dynaport Movemonitor
(DAM, McRoberts BV, The Hague, the Netherlands) and
Actigraph GT3x (ACT, Actigraph LLC Pensacola, Florida, USA)
for two periods; 1 week preceding V2 and 1 week preceding
V3. Patients were asked to wear the monitors whenever awake.
These triaxial accelerometers, worn around the waist, have been
thoroughly validated in COPD.19 20 Outputs from the activity
monitors used for assessment were not available for patients. A
valid PA measurement was defined as a minimum of two week-
days with at least eight hours of wearing time, with weekends
excluded from the analysis21 (rationale in online supplementary
material). The increase in the number of steps per day over
3 months was chosen as primary outcome. Time in at least mod-
erate intense PA (MPA), walking time and movement intensity
during walking were chosen as secondary PA outcomes.
Sedentarism has been defined as a step count lower than 5000
steps,22 and for responder analysis a clinically significant
increase in step count was defined as ≥1000 steps.23 Although
we collected data from two monitors, we report data from the
ACT in terms of step count and MPA (‘Freedson 2011’24), while
walking time and intensity during walking are based on the
DAM, more information about these decisions is included in the
online supplementary material.
Other assessments
Postbronchodilator spirometry was performed following
ATS-European Respiratory Society (ERS) recommendations25
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during V1 and V3, data were related to reference values.26 The
following clinical outcomes were collected at V2 and V3. (1)
Functional exercise capacity measured as the best of two 6-min
walk tests, following ATS-ERS guidelines;27 (2) isometric quadri-
ceps force (QF) measured with the patient fixed in 90° hip and
knee flexion;28 and (3) health status measured using the COPD
assessment test (CAT) and the clinical COPD questionnaire
(CCQ). Breathlessness was measured using the modified Medical
Research Council (mMRC) questionnaire. Exacerbation history in
the last 12 months, demographic data, medical history including
comorbidities and anthropometric data were obtained and a phys-
ical examination was performed during V1.
Quality control, safety and time consumption
In two rounds (one during the initial phase and one after
recruitment had been completed), investigators from each site
visited in a random order another site to assess protocol devia-
tions, verify data and ensure standardisation of procedures.
Adverse events were collected during the course of the trial as
well as by direct questioning during the final visit. All contacts
with patients were logged in the electronic case report file by
the investigators including the reason for and duration of the
contact.
Statistics
Based on a between-group difference of 1500 steps/day, an SD
of 3400 steps/day and a dropout rate of 20%, a need of 68
patients in each arm (total of 136) was calculated for obtaining
90% power using an α level of 0.05 (two-sided). The sample
size calculation is based on repeated measurements between two
groups and is detailed in the online supplementary material. All
statistical analyses were performed using the SAS statistical
package (V.9.3, SAS Institute, Cary, North Carolina, USA). All
analyses were based on a statistical analysis plan a priori
accepted by all authors. Data are presented as mean±SD or
median (Q1–Q3). Statistical significance was set at p<0.05 for
all these analyses. All randomised patients were encouraged to
return for the final visit and considered for these modified
intention-to-treat analyses. No imputation was made for missing
data, interpreted as ‘missing at random’.
Between-group differences were analysed using an analysis of
covariance (ANCOVA) model to adjust for potentially con-
founding factors judged to be distributed unevenly between
groups. End-of-study variables were used as the dependent vari-
able, the baseline variable as a covariate and the group factor as
the explanatory variable whose effect is to be tested. Because
randomisation was performed by centre, the adjustment by
centre was tested. Goodness of fit was assessed by means of nor-
mality of residuals. ORs for achieving a 1000 steps/day increase
in PA, defined as the minimal important difference,23 were
calculated.
As an exploratory analysis, we investigated the intervention
effect in different subgroups. Similar ANCOVA analyses as pre-
viously mentioned were performed, including the subgroup and
interaction subgroup×group factor. The different subgroups
were based on baseline data of mMRC (<2 vs ≥2), median split
of 6-min walk distance (6MWD) (<450 vs ≥450 m), comorbi-
dity (<2 vs ≥2), Global Initiative for Chronic Obstructive Lung
Disease (GOLD) quadrants (A–B vs C–D) and baseline step
count (<5000 vs ≥5000 steps/day).
RESULTS
Study population
Of the 368 enrolled patients, 343 were randomised (figure 2),
between June and December 2014. Baseline characteristics were
comparable between groups with regard to factors influencing
PA (see table 1). In total, 13 patients in the control and 12 in
the IG dropped out (figure 2). Patients who dropped out had a
lower body mass index (BMI) (p<0.01), worse QF (p<0.01)
and a worse health status (p=0.02) compared with completers
(see online supplementary material).
Main PA analyses are based on 140 UCG and 140 IG patients
with valid ACT measurements on both time points. Patients
without valid PA data had slightly worse lung function
(FEV1%pred) compared with those included in the PA analyses
(see online supplementary material). The 280 patients included
in the PA analyses wore the accelerometers for 4.7±0.6
Figure 1 Flow chart for the calculation of the new goal (steps) during the intervention period.
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weekdays with a wearing time of 806±120 min and 4.6±0.7
weekdays with a wearing time of 785±120 min, respectively,
during the baseline and final measurement (no differences
between groups). Daylight during the baseline measurement of
these patients (745±150 min) as well as changes in daylight
(−164±162 min) were comparable between groups. None of
the considered confounders remained in the ANCOVA analyses.
Patients in the IG (n=140) wore the Fitbug step counter for a
median (Q1–Q3) of 91 (84–98) % of the days they were
included in the coaching programme, representing 6.3 (5.8–6.8)
days/week.
Physical activity
IG patients had an increase over controls of mean, 95% CI
(lower limit – upper limit; ll-ul) 1469, 95% CI (973 to 1965)
steps/day (29% from baseline) and 10.4, 95% CI (6.1 to 14.7)
min/day MPA (44% from baseline), p≤0.001 for all. PA
increased in the patients in the IG (median (Q1–Q3) 4305
(2841–5851) to 4767 (3080–7949) steps/day; 14 (5–26) to 18
(6–48) min MPA) and decreased in the UCG (4643 (2932–
6955) to 4059 (2624–6332) steps/day; 15 (5–35) to 14 (3–32)
min MPA). Results were comparable for both accelerometers
used (see online supplementary material and figure 3). Including
centre in the analyses did not change the results.
Patients in the IG were 4.44, 95% CI (2.38 to 8.29) times
more likely to have a 1000 steps increase (51 (36%) vs 16
(11%) patients, p<0.001). Patients with a lower score on the
mMRC (p=0.001), those with a better 6MWD (p=0.001) and
patients in GOLD A-B (p=0.05) at baseline showed a larger
intervention effect. There was no difference based on the
baseline PA (p=0.48) or having comorbidities (p=0.30) (see
figure 4).
Other outcomes
The analyses of the other outcomes are based on all patients
who completed the study (n=159 in both groups) with data on
both baseline and final visit; more information is given in
table 2. The change in functional capacity was small but signifi-
cantly different between IG and UCG (13.4, 95% CI (3.4 to
23.5) m, p=0.01). An improvement could be observed in the
functional state domain of the CCQ (p=0.03). Other domains
of the CCQ, QF or CAT scores were not affected by the inter-
vention (see table 2).
Adverse events and contact time
In total, 48 patients (30%) in the control and 43 patients (27%)
in the IG experienced at least one exacerbation (p=0.54)
during the trial, 5 of which led to hospitalisation. Lung function
variables during the final visit were not different from baseline
variables in either group.
Eleven musculoskeletal events were described in the IG com-
pared with two in the UCG (p=0.01), none causing study
Figure 2 Consolidated Standards of Reporting Trials (CONSORT) diagram. Valid data based on two weekdays with at least eight hours of wearing
time during baseline and final visit. *No information on screening in site of Edinburgh. ACT, Actigraph; ATH, Athens; DAM, Dynaport Movemonitor;
EDI, Edinburgh; GRO, Groningen; LEU, Leuven; LON, London; PA, physical activity; ZUR, Zurich.
418 Demeyer H, et al. Thorax 2017;72:415–423. doi:10.1136/thoraxjnl-2016-209026
Chronic obstructive pulmonary disease
1e Verd. Protected by copyright.
 o
n
 M
ay 5, 2020 at Biom
edische Bibliotheek Fac G
eneeskunde - P8 /
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2016-209026 on 30 January 2017. Downloaded from 
Table 1 Baseline characteristics
Variable
UCG
n=172
IG
n=171
Female/male* 64 (37) / 108 (63) 60 (35)/111 (65)
Age (years) 67±8 66±8
BMI (kg/m2) 25.9±4.8 26.7±5.3
Active smoker* 51 (30) 39 (23)
Recent severe AECOPD* 9 (5) 8 (5)
Comorbidity* 91 (53) 102 (60)
FEV1 (%pred) 57±21 55±20
6MWD (m) 448±106 438±107
6MWD (%pred) 72±16 70±16
QF (kg) 31.6±9.5 31.0±10.9
CAT score 13 (8–19) 13 (7–20)
GOLD quadrants
(A/B/C/D)*
66 (38)/17
(10)/37 (22)/52 (30)
52 (30)/16 (9)/43
(25)/60 (35)
Step count (steps) 5120±2932 4634±2697
MPA (min) 15 (5–34) 12 (4–26)
MI (m/s2) 1.86±0.36 1.82±0.30
Walking time (min) 72±36 69±34
Sedentary* 95 (58) 104 (64)
QF was not measured in 2 centres, QF was missing in 35 control and 32 intervention
patients, 6MWD was missing in 2 intervention patients. Steps and MPA are measured
by the ACT, MI and walking time are measured by DAM; being sedentary has been
defined as a step count measured by ACT <5000 steps/day. A valid baseline PA
measurement was present in 165 control and 162 intervention patients for outcomes
measured by ACT (steps, MPA) and in 155 control and 156 intervention patients for
outcomes measured by DAM (MI, walking time).
Data are expressed as mean±SD and median (Q1–Q3). *Data expressed as n (%).
6MWD, 6-min walk distance; ACT, Actigraph; BMI, body mass index; comorbidity,
presence of at least one comorbidity; CAT, COPD assessment test; DAM, Dynaport
Movemonitor; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IG,
intervention group; MI, movement intensity during walking; MPA, time in at least
moderate intense activity; n, number of patients; PA, physical activity; QF, quadriceps
force; recent severe AECOPD, an acute exacerbation of COPD requiring hospitalisation
within 1 month prior to inclusion; UCG, usual care group.
Figure 3 Changes in physical activity by group. Patients in the intervention group presented in solid line, and patients in the control group
presented as dotted line. Data are presented as mean, 95% (ll to ul); Steps and time in at least moderate physical activity (MPA) analyses are
based on Actigraph measurement and include 140 control and 140 intervention patients, Walking time and movement intensity (MI) are based on
Dynaport Movemonitor measurement and include 132 control and 129 intervention patients. *indicates significant within-group changes (p<0.05).
NS, not significant.
Figure 4 Between-group differences in mean step count, adjusted for
baseline data. Data are presented for the different subgroups, based on
baseline characteristics; Global Initiative for Chronic Obstructive Lung
Disease (GOLD) quadrants based on modified Medical Research Council
(mMRC) to classify symptoms; number of patients mMRC (<2 vs ≥2;
166 vs 114), 6-min walk distance (6MWD) (≥450 vs <450 m; 140 vs
138), comorbidity (<2 vs ≥2; 238 vs 42), GOLD quadrants (A–B vs C–
D; 129 vs 151), steps (≥5000 vs <5000; 115 vs 165); data represented
as mean between-group effect with 95% CI. Numbers indicate the
percentage of patients of the subgroup in the control/intervention
group. Analyses are based on 278 patients for 6MWD and 280 for
mMRC, comorbidity, GOLD and physical activity subgroups.
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discontinuation. Of those in the IG, only one event required
treatment (knee inflammation). One patient experiencing back
pain was advised to lower his PA in the acute situation. Another
patient with back pain was observed for 1 day in hospital,
without any treatment being initiated. Three events were judged
as possibly related to the intervention by the investigators (two
patients with back pain, one patient with a rib fracture), one
event (back pain) was judged as unlikely related. Other adverse
events, all not related to the study protocol, were cardiovascular
problems (n=2), diagnosis of a toe melanoma (n=1), urinary
problems (n=2), and gastrointestinal problems (n=3).
Patients in the IG who completed the trial were contacted for
a median (Q1–Q3) of 6 (4–9) times (range 0–25 times), with a
total time consumption for the investigator of 50 (30–95) min
per patient (range 0–375 min). Seventy-five per cent of contacts
were initiated by the application (‘flags’), the minority (25%)
were patient driven. More details are available in the online
supplementary material.
DISCUSSION
Our study demonstrates the effectiveness of a 12-week semiau-
tomated telecoaching intervention in increasing PA in a broad
spectrum of COPD. Patients with a better exercise capacity and
those with less symptoms had a more favourable response.
Strengths and weakness of the study
To the best of our knowledge, this is the first multicentre trial
showing the effectiveness of a telecoaching intervention in
patients with COPD using triaxial accelerometry as an outcome
measure. The paper reports on the effect of the intervention on
patients included in six centres across Europe, including
primary, tertiary care and rehabilitation centres, which increases
the generalisability of the results. This study included people
with a wide spectrum of disease severity and a wide range of PA
levels without excluding patients who were ‘active’ at the start
of the programme nor those not able to leave the house, as can
be observed by the representation of all mMRC scores. Because
of these liberal inclusion criteria, the present trial is likely to be
relevant to patients seen in routine clinical practice. By provid-
ing a smartphone, the inclusion did not depend on any previous
experience, even in this elderly population. Only four patients
dropped out of the study because they were not able to work
with the smartphone application. It could be argued that the
intervention would have attracted the more educated COPD
population, leading to a possible problem of external validity.
This would nevertheless not have changed the interpretation of
the present results. The feasibility of using smartphones for
wireless transmission (via 4G) of data in this population is in
line with previous studies.29 30 The algorithm used to revise the
targets every week was based on having at least four days of
step counter data. Compliance was not an issue as patients wore
the step counter >6 days out of 7. Whether the intervention
translates to long-term maintenance of higher PA levels has not
yet been investigated.
Some remarks should be made concerning the interpretation
of our results. Based on the present study, we cannot state
whether all component parts of this intervention were essential.
Providing a step counter in combination with goal setting could
potentially be equally effective.15 The present application
however, using a more complex technology interface, allowed
clinicians to have insight into the compliance of patients and
intervene if patients were unable to cope with the preset goals.
Another advantage of such interventions is the standardisation
of the intervention, avoiding bias related to the investigator pro-
viding the coaching. This makes the intervention, on the one
hand, feasible to investigate in a multicentre trial and, on the
other hand, it is potentially applicable to routine clinical practice
without specific expertise requirements. One could argue that
Table 2 Secondary outcomes
Within-group Between-group
Variable Baseline 3 m meanΔ 95% CI (ll to ul) meanΔ 95% CI (ll to ul)* p Value*
6MWD (m)
UCG 450±106 449±118 −0.81 (−7.7 to 6.1) 13.4 (3.40 to 23.5) 0.009
IG 444±106 457±108 12.7 (5.4 to 20.1)
QF (kg)
UCG 32.0±9.7 31.7±9.3 −0.356 (−1.59 to 0.88) 0.340 (−1.38 to 2.06) 0.697
IG 31.7±11.0 31.8±10.3 0.102 (−1.35 to 1.55)
CAT (points)
UCG 13 (8–18) 13 (9–20) 1.09 (0.032 to 2.15) −0.57 (−1.88 to 0.74) 0.391
IG 13 (7–20) 14 (9–19) 0.62 (−0.346 to 1.59)
CCQmental state
UCG 1 (0–2) 1 (0–2) 0.198 (−0.116 to 0.51) −0.133 (−0.326 to 0.061) 0.178
IG 1 (0–2.5) 1 (0–2.5) −0.031 (−0.320 to 0.257)
CCQfunctional state
UCG 1.5 (0.75–2.5) 1.75 (0.75–2.75) 0.64 (0.060 to 1.23) −0.203 (−0.382 to −0.024) 0.026
IG 1.5 (1–2.75) 1.5 (1–2.75) −0.069 (−0.639 to 0.50)
CCQsymptoms
UCG 1.75 (1.5–2.75) 2 (1.25–2.75) 0.94 (0.281 to 1.59) −0.085 (−0.263 to 0.094) 0.352
IG 1.75 (1.25–2.5) 1.75 (1.25–2.5) 0.97 (0.378 to 1.56)
Data are presented as mean±SD, median (Q1-Q3), within-group and between-group differences are presented as mean Δ 95% CI (ll to ul).
Analyses are based on 299 (6MWD, 94% of completers), 243 (QF, 76% of completers), 317 (CAT, 100% of completers) and 316 (CCQ, 99% of completers) patients.
*Adjusted for baseline outcome.
6MWD, 6-min walk distance; CAT, COPD assessment test; CCQ, clinical COPD questionnaire; IG, intervention group; QF, quadriceps force; UCG, usual care group.
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the different parts of the intervention, or the combination of
these, rather than the medium used to provide these (smart-
phone) were essential. In this case, the present intervention
could be provided by any kind of modern communication (eg,
internet-mediated via any interface). The present authors are
convinced that the intervention can be adapted to the prefer-
ence of communication given by the patient or patient popula-
tion. It could as well be debated that the contact with the
investigator rather the telecoaching could have resulted in the
present results. However, this is unlikely as adding a behavioural
intervention based on face-to-face contacts in patients following
a rehabilitation programme did not result in an enhanced PA
level.31
It is of interest that in both the IG and the UCG group the
non-completers had a more severe disease judged by quadriceps
strength, BMI and CAT score; moreover, those unable to under-
take valid PA monitoring had a lower FEV1. This mirrors previ-
ous findings that these patients are less likely to complete an
intervention.32 We acknowledge therefore that some patients
with the most severe disease may need a more personal
approach such as participation in a pulmonary rehabilitation
programme before they engage in PA coaching programmes.
The IG patients reported more musculoskeletal problems com-
pared with the UCG. This information should be interpreted
with some caution as the frequency of contact with patients in
the IG was higher; patients in the UCG only reported adverse
events at the end of the trial. Knowing that almost none of
these events required any treatment, it may be that mild adverse
events were therefore under-reported in the UCG. This bias
could have been minimised by providing a diary to patients in
the control group. On the other hand, minor transient musculo-
skeletal problems are not unexpected when sedentary people
start an activity programme. PA is highly dependent on the
season of measurement.33 Therefore, a limitation of the present
trial is the narrow inclusion between June and December 2014.
This can be seen as by the mean decrease in daylight over time,
a proxy for season. This likely explains the decrease in PA seen
in the control group. Although this influences the within-group
results, it does not change the between-group comparisons as
the groups were randomly assigned and therefore comparable
(including change in daylight). Our results show that patients
can be motivated to be active, even during periods of worse
weather conditions. Lastly, neither patients nor investigators
were blinded to treatment allocation. However, by using the
objective PA measurement, the lack of blinding of investigator
will not have influenced the primary end point. Nevertheless,
we do acknowledge the lack of blinding could have minimally
influenced the 6MWD results.
Comparison with other studies
Several studies have used step counters to provide real-time
feedback on PA in combination with goal setting in comparable
patient groups.14 15 17 The weighted mean effect of these
studies was 1259 steps/day improvement over controls. One
study, which used a pedometer intervention and monthly
face-to-face meetings, showed a significantly larger effect.15 In
that study, exercise capacity was relatively well preserved (463 m
6MWD), perhaps providing more window for improvement as
there was a larger functional reserve.34 It is clear that coaching
programmes with the specific aim of increasing PA lead to larger
improvements in amount of PA compared with rehabilitation,35
and pharmacology.11 12 In the present study, patients in the IG
were four times more likely to increase their PA by >1000
steps. This increment was defined a priori because it has been
defined as the minimal important difference23 and because of its
relation with the decreased risk for COPD-related hospitalisa-
tion or mortality.36 The present intervention was effective irre-
spective of patients’ baseline PA being above or below 5000
steps. Shifting to more active PA provides additional health ben-
efits in healthy elderly and special populations.3 This supports
the concept that aiming for an increase in PA level to lift
patients above the ‘sedentary lifestyle index’ of 5000 steps,22 or
the ‘active’ threshold of 7500 steps,3 is important. The objective
of this intervention was to enhance PA by empowering patients
and motivating them to engage in more daily activity. It comes
as no surprise that the intervention, while successful in enhan-
cing PA, had only a minimal impact on exercise capacity and
muscle strength. This observation is in line with others15 and is
likely due to the relatively low intensity of PA, insufficient to
enhance skeletal muscle function. Indeed, the time in MPA only
increased by 10 min/day. This may yield health benefits but is
not an adequate exercise training stimulus to incur in training
effects in the peripheral muscle. Our findings are likely import-
ant from a healthcare perspective since the present intervention
could easily be combined with a formal exercise training inter-
vention or other interventions with a more direct impact on
exercise capacity potentiating the effects of both interventions.
Future perspectives
The present intervention should be seen as a promising tool as
an increased number of patients own a smartphone (mobile
broadband is the most dynamic Information and communica-
tions technology (ICT) market segment with a 12-fold increase
in users worldwide between 2007 and 201537). In the present
study, patients were equipped with a smartphone. The interven-
tion will become more clinically available and cost-effective if
patients own their own smartphone device. It can be envisaged
that this intervention can be embedded in a broader healthcare
intervention using a smartphone (m-health). In any case, the
coaching tools available on the market should be adapted for
users with chronic diseases. Given the limited effect of this
intervention on exercise capacity, the impact of delivering this
telecoaching intervention in the context of a pulmonary
rehabilitation programme or further optimised pharmacotherapy
could be a future investigation.
CONCLUSION
In conclusion, the present study shows the effectiveness of a
12-week semiautomated telecoaching programme (application
installed on a smartphone device) and a step counter providing
direct feedback on total daily number of steps, walking time,
time in at least moderate PA and movement intensity during
walking in patients with COPD across the whole disease
spectrum.
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